Macrophage Migration-Inhibitory Factors
"Macrophage Migration-Inhibitory Factors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins released by sensitized LYMPHOCYTES and possibly other cells that inhibit the migration of MACROPHAGES away from the release site. The structure and chemical properties may vary with the species and type of releasing cell.
| Descriptor ID |
D008263
|
| MeSH Number(s) |
D12.644.276.374.480.625 D12.776.467.374.480.625 D23.125.477.500 D23.529.374.480.625
|
| Concept/Terms |
Macrophage Migration-Inhibitory Factors- Macrophage Migration-Inhibitory Factors
- Macrophage Migration Inhibitory Factors
- Migration-Inhibitory Factors, Macrophage
- Macrophage Migration Inhibition Factors
- Migration Inhibition Factors, Macrophage
|
Below are MeSH descriptors whose meaning is more general than "Macrophage Migration-Inhibitory Factors".
Below are MeSH descriptors whose meaning is more specific than "Macrophage Migration-Inhibitory Factors".
This graph shows the total number of publications written about "Macrophage Migration-Inhibitory Factors" by people in this website by year, and whether "Macrophage Migration-Inhibitory Factors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Macrophage Migration-Inhibitory Factors" by people in Profiles.
-
MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Carcinogenesis. 2024 Aug 12; 45(8):582-594.
-
Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis. 2022 02 04; 13(2):117.
-
MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020 12 06; 9(1):1846915.
-
MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. Blood. 2020 11 26; 136(22):2557-2573.
-
Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. Br J Clin Pharmacol. 2020 09; 86(9):1836-1848.
-
ZFPM2-AS1, a novel lncRNA, attenuates the p53 pathway and promotes gastric carcinogenesis by stabilizing MIF. Oncogene. 2018 11; 37(45):5982-5996.
-
Macrophage migration inhibitory factor (MIF) gene is associated with adolescents' cortisol reactivity and anxiety. Psychoneuroendocrinology. 2018 09; 95:170-178.
-
Multi-nucleated cells use ROS to induce breast cancer chemo-resistance in vitro and in vivo. Oncogene. 2018 08; 37(33):4546-4561.
-
Identification of Iguratimod as an Inhibitor of Macrophage Migration Inhibitory Factor (MIF) with Steroid-sparing Potential. J Biol Chem. 2016 Dec 16; 291(51):26502-26514.
-
Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response. J Natl Cancer Inst. 2016 11; 108(11).